Advertisement


Andrea Necchi, MD, on Bladder Cancer: Phase II Results With Pembrolizumab Monotherapy

2023 ASCO Genitourinary Cancers Symposium

Advertisement

Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses new data from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The findings suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy. (Abstract LBA442).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The cohort B of KEYNOTE-057 study investigated pembrolizumab monotherapy in patients with high-risk and non-muscle invasive disease, unresponsive to BCG. The 057 study is a multi-cohort study. The cohort A of the study included the patients with the carcinoma in situ component to with or without papillary disease, unresponsive to BCG who were ineligible for, or declined, radical cystectomy. Results from cohort A presented the clinical complete response rate at 3 months of 40%, with most of the complete responses maintained over time, and resulted in FDA approval of pembrolizumab in the CIS BCG unresponsive population. The results of cohort B that have been presented at this meeting focused on a bit different patient population, represented by patients without any carcinoma in situ component, and with the only papillary pTa high-grade or any pT1 disease without CIS. This is a very special population for which we do not have any robust standard of care. This is the focus of the cohort B of the study. The design of the study was the same. Pembrolizumab monotherapy until 2 years every 3 weeks or until disease occurrence or progression with high-risk disease. The primary endpoint of this court was 12-month disease-free survival for high-risk disease. Secondary endpoints included the progression-free survival, disease-free survival for any disease occurrence, and the overall survival and quality of life parameters. The main findings of the KEYNOTE-057 cohort B resulted in 12-month disease-free survival for high-risk disease of almost 43%, which sets among the most robust data already available with this special population. The progression-free survival to any stage progression or stage disease or death was 88%, and progression to muscle-invasive metastatic disease or death was a similar, 88%. There were no new safety signals, no treatment related death. Results, in terms of safety, were consistent with the already available data with pembrolizumab in various disease settings, including cohort A. Quality of life parameters and quality of life scores were maintained over time, were stable over time in patients who continue treatment with or without any recurrence. So, how can we move forward with this data? Of course, the US FDA requires a randomized study in order to set new standards with newer therapies, and particularly systemic therapies in this special patient population. I think that the data from the cohort B of the study may allow us to re-discuss the need for doing a randomized study in this very difficult to treat population without any robust standard of care intravesical therapy, without any clinical trial option, because of the fact we that we currently lack robust data on standard of care therapies to compare with any newer therapies, intravesically or as a systemic therapy. So I think that the good point of this study is that it will likely generate a new discussion at [inaudible 00:03:21], including regulators, patient advocates, and physicians.

Related Videos

Kidney Cancer

Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab

Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab. The regimen appears to result in substantial treatment-free survival with few treatment-related adverse events. (Abstract 604).

Bladder Cancer
Kidney Cancer
Prostate Cancer

Updates From City of Hope on Renal Cell, Prostate, and Urothelial Cancers

Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate, and urothelial cancer trials to more accurately reflect the real-world population and reducing exclusion criteria. (Abstract 662, 612, 34, 453)

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: New Findings on Treatment With Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses results from the FORMULA-509 study, which compared postoperative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide, after radical prostatectomy. The study suggested that adding AAP and apalutamide to salvage radiotherapy, plus 6 months of androgen-deprivation therapy, may improve outcomes, particularly in the subgroup of patients with a prostate-specific antigen level higher than 0.5 ng/mL. (Abstract 303).

Kidney Cancer

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Phase III Results on Cabozantinib, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discusses new data from the COSMIC-313 study of patients with advanced renal cell carcinoma of IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk. Those who received cabozantinib instead of placebo with nivolumab and ipilimumab as first-line treatment seemed to experience improved progression-free survival. A subgroup analysis suggested the benefit was primarily in patients with an intermediate risk. Follow-up for overall survival is ongoing. (Abstract 605).

Prostate Cancer

Alan H. Bryce, MD, on Prostate Cancer: Phase III Results on Rucaparib, Docetaxel, and Androgen Pathway Inhibitor Therapy

Alan H. Bryce, MD, of the Mayo Clinic, discusses the final results of the primary endpoint of rPFS and interim results on overall survival among patients with chemotherapy-naive metastatic castration-resistant prostate cancer. The data showed that rucaparib improved radiographic progression-free survival compared with either docetaxel or abiraterone and enzalutamide in disease with BRCA1/2 alterations. (Abstract 18).

Advertisement

Advertisement




Advertisement